Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort
- PMID: 20565900
- PMCID: PMC2905421
- DOI: 10.1186/1471-2334-10-179
Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort
Abstract
Background: Although a dramatic decrease in AIDS progression has been observed after Highly Active Anti Retroviral Therapy (HAART) in both low- and high-resource settings, few data support that fact in low-resource settings.This study describes the incidence of AIDS-defining illnesses (ADI) after HAART initiation and analyzes their risk factors in a low-resource setting. A focus was put on CD4 cell counts and viral load measurements.
Methods: 404 HIV-1-infected Senegalese adult patients were enrolled in a prospective observational cohort and data censored as of April 2008. A Poisson regression was used to model the incidence of ADIs over two periods and to assess its association with baseline variables, current CD4, current viral load, CD4 response, and virological response.
Results: ADI incidence declined from 20.5 ADIs per 100 person-years, 95% CI = [16.3;25.8] during the first year to 4.3, 95% CI = [2.3;8.1] during the fourth year but increased afterwards. Before 42 months, the decrease was greater in patients with clinical stage CDC-C at baseline and with a viral load remaining below 1000 cp/mL but was uniform across CD4 strata (p = 0.1). After 42 months, 293 patients were still at risk. The current CD4 and viral load were associated with ADI incidence (decrease of 21% per 50 CD4/mm3 and of 61% for patients with a viral load < 1000 cp/mL).
Conclusions: During the first four years, a uniform decline of ADI incidence was observed even in patients with low CD4-cell counts at HAART initiation as long as the viral load remained undetectable. An increase was noted later in patients with immunologic and virological failures but also in patients with only virological failure.
Figures


Similar articles
-
AIDS across Europe, 1994-98: the EuroSIDA study.Lancet. 2000 Jul 22;356(9226):291-6. doi: 10.1016/s0140-6736(00)02504-6. Lancet. 2000. PMID: 11071184
-
Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.Clin Infect Dis. 2006 Mar 15;42(6):878-84. doi: 10.1086/500210. Epub 2006 Feb 8. Clin Infect Dis. 2006. PMID: 16477568
-
Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.Pediatr Infect Dis J. 2013 Apr;32(4):354-60. doi: 10.1097/INF.0b013e318278b222. Pediatr Infect Dis J. 2013. PMID: 23099424
-
The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.J Infect. 2001 Feb;42(2):134-9. doi: 10.1053/jinf.2001.0810. J Infect. 2001. PMID: 11531320
-
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.Arch Intern Med. 2005 Feb 28;165(4):416-23. doi: 10.1001/archinte.165.4.416. Arch Intern Med. 2005. PMID: 15738371
Cited by
-
Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods.PLoS One. 2011;6(11):e27763. doi: 10.1371/journal.pone.0027763. Epub 2011 Nov 17. PLoS One. 2011. PMID: 22114687 Free PMC article. Clinical Trial.
-
HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.J Clin Microbiol. 2013 Feb;51(2):578-84. doi: 10.1128/JCM.02452-12. Epub 2012 Dec 12. J Clin Microbiol. 2013. PMID: 23241378 Free PMC article.
-
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821. J Acquir Immune Defic Syndr. 2013. PMID: 23274931 Free PMC article.
-
Increased Levels of Caspase-1 and IL-1β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort.Open Forum Infect Dis. 2023 Nov 7;10(11):ofad539. doi: 10.1093/ofid/ofad539. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 37953818 Free PMC article.
-
Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia.HIV AIDS (Auckl). 2015 May 12;7:137-44. doi: 10.2147/HIV.S79545. eCollection 2015. HIV AIDS (Auckl). 2015. PMID: 25999763 Free PMC article.
References
-
- Mocroft A, Sabin C, Youle M. Changes in AIDS-Defining Illnesses in a London Clinic, 1987-1998. JAIDS. 1999;21:401–407. - PubMed
-
- Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic. J Infect. 2001;42(2):134–139. - PubMed
-
- Palella FJ, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G, Aschman D, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. - PubMed
-
- Bonnet F, Chene G, Thiebaut R, Dupon M, Lawson-Ayayi S, Pellegrin JL, Dabis F, Morlat P. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med. 2007;8(8):547–554. - PubMed
-
- Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. Jama. 1999;282(23):2220–2226. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous